Cholesterol Guidelines Move Forward as Risk Tool Debated

Concerns raised by two Harvard researchers over new treatment guidelines for heart risk shouldn’t change the method used for determining what patients should get cholesterol-lowering drugs, top U.S. heart doctors said today at the American Heart Association meeting in Dallas.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.